James Healy

General Partner


Jim joined Sofinnova in 2000 as a General Partner. He focuses on funding clinical stage private and publicly traded bio-pharmaceutical companies. He has financed and served on the board of ten companies which received drug approvals from either FDA or EMA, thirteen companies which completed initial public offerings, and eleven companies which were acquired as private or as public companies. Jim represents Sofinnova on the board of directors of Amarin (AMRN), Ascendis (ASND), Auris (EARS), Coherus (CHRS), Edge (EDGE), Natera (NTRA), Audentes, Iterum, Obseva, and Nucana. Previous investments and board memberships include Anthera Pharmaceuticals (ANTH), Cellective Therapeutics (acquired by AstraZeneca), CoTherix (CTRX, acquired by Actelion), Durata Therapeutics (DRTX, acquired by Actavis), InterMune (ITMN, acquired by Roche), Movetis (MOVE, acquired by Shire), Nextwave Pharmaceuticals (acquired by Pfizer), Novacea (NOVC, merged with Transcept), Preglem (acquired by Gideon Richter), Prestwick (acquired by Biovail), and Salveo Specialty Pharmacy (acquired by Catamaran).

Prior to Sofinnova, Jim worked at Bayer (Miles) and Sanderling. In 2011, Jim won the IBF Risk Innovator Award and was named as one of the industry’s top Life Science investors in 2013 by Forbes Magazine. Jim has authored or co-authored thirteen peer reviewed articles and invited reviews, including three papers published in Nature.

Jim received his MD and PhD in Immunology from Stanford University, through a scholarship from the NIH Medical Scientist Training Program. At Stanford, he was a Beckman Scholar and received a Novartis Bursary Award. Jim graduated with a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California at Berkeley where he graduated with Honors and received a Departmental Citation. Previously, Jim served as a member of the Executive Board of the College of Letters and Science at the University of California Berkeley and has lectured on entrepreneurship at Stanford University. Jim currently is a Director on the Board of the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO).

Assistant: Tiffany Davis

Email: davis@sofinnova.com


(650) 681-8422


Representative Investments